Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.

摘要: Fibulin-3 (FBLN3) was recently presented as a promising novel biomarker for malignant pleural mesothelioma (MPM), warranting independent validation studies. ELISA used to measure cellular and secreted FBLN3 in cell lines, plasma of xenograft tumour-bearing mice, from two series MPM non-MPM patients fluid third series. Diagnostic prognostic potential assessed by receiver operating characteristics curve analysis Kaplan–Meier method, respectively. expressed all benign mesothelial lines tested, correlation observed between protein expression levels. Human detectable suggesting that cells contribute levels circulating FBLN3. Plasma significantly elevated the Sydney cohort, but not Vienna diagnostic accuracy low (63%, (95% CI: 50.1–76.4) 56% 41.5–71.0), respectively). Although effusions were different cases controls, effusion found be independently associated with prognosis (hazard ratio 9.92 2.14–45.93)). These data confirm value FBLN3, question this patients.